Qureight Appointed Imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics Expands
- Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models